Development of P2X3 Ion Channel MAbs for the Treatment of Pain
Award amount
$1,428,459Program and phase
SBIR · Phase IIAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- INTEGRAL MOLECULAR INC
- Proposal award date
- 2014-09-15
- Contract end date
- 2018-02-28
- UEI
- DY9KSWE8EJB8
- Solicitation number
- PA11-335
- Topic code
- 100
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- ANTIBODY REAGENTS FOR IMMUNOLOGIC ANALYSIS OF UNDER-REPRESENTED MAMMALIAN MODELS
- High-throughput Discovery of Antibodies against Understudied Membrane Proteins using mRNA
- Specificity Screening Drug Development Tool for Biotherapeutic Safety
- Development of Safe and Rapid Reporter Viruses for Studying Pathogenic and Pandemic Viruses
- Reagents for Immunologic Analysis of Under-represented Mammalian Models
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- First-in-class TREM-1 inhibitors for neovascular retinal diseases
- Development of a Novel Biosensor to Accelerate Investigations of the Gut Microbiome
- Magnetic Lipid Nanoprobe Platform for Rapid, Highly-Efficient, and Cost-Effective Isolation of Extracellular Vesicles from Non-Invasive Bodily Fluids
- Scale-up and Manufacturing of STLR-201, an off-the-shelf regenerative therapeutic for Sjogren's syndrome-related dry eye disease
- Integrated assays of single-cell dynamics and molecular phenotype for cell therapy manufacturing
Research funding history
48 SBIR/STTR records share this UEI (2002–2025). Reported award amounts total $32,839,788. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services